Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

2.86
-0.1100-3.70%
Post-market: 2.880.0201+0.70%19:55 EDT
Volume:4.92M
Turnover:14.35M
Market Cap:554.84M
PE:-3.76
High:2.99
Open:2.99
Low:2.86
Close:2.97
52wk High:6.44
52wk Low:2.56
Shares:194.00M
Float Shares:164.00M
Volume Ratio:1.45
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7600
EPS(LYR):-0.9999
ROE:-28.87%
ROA:-17.20%
PB:1.17
PE(LYR):-2.86

Loading ...

Unusually active option classes on open June 24th

TIPRANKS
·
Jun 24

Altimmune Initiated at Outperform by Leerink Partners

Dow Jones
·
Jun 22

Leerink Partners Initiates Altimmune at Outperform With $10 Price Target

MT Newswires Live
·
Jun 22

Altimmune Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $10

THOMSON REUTERS
·
Jun 22

Altimmune initiated with an Outperform at Leerink

TIPRANKS
·
Jun 22

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Reuters
·
Jun 22

Altimmune plans to move headquarters to Morristown, New Jersey from Maryland

Reuters
·
Jun 17

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

GlobeNewswire
·
Jun 11

Boehringer - 84.2% Patients on Survodutide Cut Liver Fat by at Least 30% VS 24.3% on Placebo in Synchronize-Masld

THOMSON REUTERS
·
Jun 08

Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat

Reuters
·
Jun 08

Boehringer - Survodutide Drug Showed 34% Visceral and 63% Liver Fat Reduction, Minimized Lean Mass Loss

THOMSON REUTERS
·
Jun 08

H.C. Wainwright Sticks to Their Buy Rating for Altimmune (ALT)

TIPRANKS
·
Jun 04

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

GlobeNewswire
·
Jun 03

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

GlobeNewswire
·
Jun 01

Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide

TIPRANKS
·
May 29

Altimmune Says Pemvidutide Data Show Metabolic Improvements in MASH Patients

MT Newswires Live
·
May 28

Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Icon (ICLR) and AIM ImmunoTech (AIM)

TIPRANKS
·
May 28

Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease

MT Newswires Live
·
May 27

Altimmune says pemvidutide shows fibrosis regression in MASH in IMPACT Phase 2b qFibrosis analysis

Reuters
·
May 27

New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026

GlobeNewswire
·
May 27